RxDoctor Payments DataLook up a doctor →

Omid Lesani, MD

Urology · Las Vegas, NVNPI 1245242957

Payments from drug & device makers

$26,840in general payments, 2019–2025

Across 394 payments — averaging $68.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$13K
  • Histosonics, Inc.$2K
  • Boston Scientific$2K
  • Teleflex LLC$2K
  • Astellas Pharma US Inc$920
  • Procept Biorobotics Corporation$800
  • plus $6K from 38 others

What the payments were for

  • Speaking & faculty fees$3,12512%
  • Travel & lodging$3,97815%
  • Food & beverage$11,90144%
  • Education$7,19927%
  • Gifts$6372%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,840 in reported general payments places this provider in the 85th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$294,096
Medicare patients
728
Services billed
3,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide19$178,628
OrgovyxRelugolix35$93,126
MyrbetriqMirabegron62$48,848
GemtesaVibegron26$24,222
Tamsulosin Hcl341$3,775
Oxybutynin Chloride ErOxybutynin Chloride123$2,479
Finasteride140$1,509
Silodosin11$1,055
Alfuzosin Hcl ErAlfuzosin Hcl54$1,011
Estradiol15$967
Methenamine Hippurate21$939
Oxybutynin Chloride90$863
Dutasteride35$852
CefuroximeCefuroxime Axetil20$168
Sildenafil Citrate28$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$920$227,47681 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$714$117,34861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 63 urology providers in Nevada.

Other urology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →